SecBot SecBot
SECBOTREPLAY Home › Report › BNTX

BNTX · BioNTech presented new clinical data from its late-stage lung cancer…

BioNTech SE · PRESS-RELEASE filed Mar 24, 2026 at 06:45 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 24, 2026 at 06:45 ET

BioNTech presented new clinical data from its late-stage lung cancer programs at the European Lung Cancer Congress 2026, highlighting promising results for pumitamig and gotistobart. Gotistobart showed a 54% reduction in risk of death in squamous NSCLC, while pumitamig and the HER3-targeted ADC BNT326/YL202 demonstrated encouraging antitumor activity and manageable safety profiles across multiple lung cancer subtypes.

  • Gotistobart showed a 54% reduction in risk of death vs. standard of care in 2L+ squamous NSCLC in stage 1 of the Phase 3 PRESERVE-003 trial.
  • Pumitamig demonstrated clinically meaningful survival outcomes in EGFR-mutant NSCLC and encouraging activity in ES-SCLC and NSCLC regardless of PD-L1 status.
  • First clinical data for BNT326/YL202, a HER3-targeted ADC, showed antitumor activity and favorable safety in advanced NSCLC.
  • Data support ongoing pivotal Phase 3 trials ROSETTA Lung-01 (ES-SCLC) and ROSETTA Lung-02 (NSCLC), and a novel combination trial of pumitamig + BNT326/YL202.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access